论著
目的 探讨血清心型脂肪酸结合蛋白(H-FABP)、血管生成素-1(Ang-1)在急性大血管闭塞性卒中(AIS-LVO)静脉溶栓桥接支架取栓患者预后中的评估价值。方法 选择2019年1月—2021年5月80例AIS-LVO患者作为研究对象,均接受静脉溶栓桥接支架取栓治疗,检测术前血清H-FABP、Ang-1水平,术后随访90 d将患者分为预后良好组(n=57)与预后不良组(n=23)。结果 两组在高血压、冠心病、心房颤动、急性卒中治疗低分子肝素试验(TOAST)分型、侧支循环、术前H-FABP、术前Ang-1方面存在差异(P<0.05)。多因素 Logistic 回归分析结果显示,高血压、心房颤动、心源性梗死型、侧支循环为0 ~1 级、术前H-FABP≥10.0 ng/L、术前Ang-1<5.25 ng/mL是AIS-LVO静脉溶栓桥接支架取栓患者预后不良的危险因素。术前血清H-FABP预测术后90 d预后不良的AUC为0.728(95%CI:0.368~0.918),灵敏度、特异度分别为66.68%、58.92%。术前血清Ang-1预测术后90 d预后不良的AUC为0.773(95%CI:0.592~1.129),灵敏度、特异度分别为70.35%、63.92%。H-FABP联合Ang-1预测术后90 d预后不良的AUC为0.854(95%CI:0.652~0.957),灵敏度、特异度分别为77.18%、71.82%。结论 静脉溶栓桥接支架取栓治疗AIS-LVO患者的预后受到多种危险因素的影响,其中术前血清H-FABP和Ang-1是具有前景的预后预测因子。
Objective To investigate the prognostic value of serum heart-type fatty acid binding protein(H-FABP)and angiopoietin-1(Ang-1)in patients with acute ischemic stroke-large vessel occlusion(ALS-LVO)undergoing venous thrombolytic bridging stent thrombectomy.Methods A total of 80 patients with ALS-LVO from January 2019 to May 2021 were selected as the study subjects,treated with intravenous thrombolytic bridging stent thrombectomy,and their serum H-FABP and Ang-1 levels were measured before operation.After 90 days of follow-up,the patients were divided into good prognosis group(n=57)and poor prognosis group(n=23).Results There were significant differences between the two groups in hypertension,coronary heart disease,atrial fibrillation,TOAST classification,collateral circulation,preoperative H-FABP,and preoperative Ang-1(P<0.05).Multivariate logistic regression analysis showed that hypertension,atrial fibrillation,cardiogenic infarction type,collateral circulation of 0~1 grade,preoperative H-FABP≥10.0 ng/L,preoperative Ang-1<5.25 ng/mL were independent risk factors for poor prognosis of ALS-LVO patients treated with venous thrombolytic bridging stents.The AUC of preoperative serum H-FABP predicting poor prognosis 90 days after operation was 0.728(95%CI:0.368~0.918),with sensitivity and specificity of 66.68% and 58.92% respectively.The AUC of preoperative serum Ang-1 predicting poor prognosis 90 days after surgery was 0.773(95%CI:0.592~1.129),with sensitivity and specificity of 70.35% and 63.92% respectively.The AUC predicted by H-FABP combined with Ang-1 for poor prognosis 90 days after operation was 0.854(95%CI:0.652~0.957),and the sensitivity and specificity were 77.18% and 71.82% respectively.Conclusions The prognosis of patients with ALS-LVO treated with intravenous thrombectomy bridging stent thrombectomy is affected by many risk factors,among which preoperative serum H-FABP and Ang-1 are promising prognostic factors.
论著
目的 观察改良直接抽吸取栓术(ADAPT)治疗急性前循环大动脉栓塞性脑卒中的有效性与安全性。方法 回顾性分析2022年3月—2023年2月在广州市第一人民医院采用改良ADAPT治疗急性前循环大动脉栓塞性脑卒中的12例患者临床资料。该改良技术核心是血栓抽吸导管或颅内支持导管管头明确越过血栓后才开始直接使用20 mL的注射器进行手动持续抽吸;所有患者术后依据临床症状和影像表现启动规范抗凝药物治疗,每月门诊随访观察有无再发卒中。结果 12例患者闭塞血管均成功再通,其中改良脑梗死溶栓(mTICI )2b~2c级3例(25%),mTICI 3级9例(75%);从穿刺到血管再通平均时间为37.7 min,首次取栓再通8例(66.7%),其中颈内动脉闭塞首次取栓再通成功率达80%,出院时平均美国国立卫生研究院卒中量表(NIHSS)评分(9.00±9.22)分,与术前基础NIHSS评分相比,平均下降7分,术后90 d功能恢复良好(mRS评分0~2分)9例(75%);术后脑出血3例(25%),其中1例为小点状出血(HI1)而无明显症状、1例为血肿<梗死面积的30%并有轻微占位效应的出血(PH1)恢复良好、1例为血肿>梗死面积的30%并有明显占位效应的出血(PH2)术后自动出院,12例患者筛查病因均发现有心房纤颤,9例患者术后依据临床症状和影像表现在早期开展规范抗凝二级预防管理后无再复发。结论 改良ADAPT是治疗急性大动脉栓塞性脑卒中的一种安全可行选择,血管再通效率高,血栓逃逸概率低、临床疗效良好。对心房纤颤患者实施规范抗凝管理可有效预防脑卒中复发。
Objective To observe the efficacy and safety of modified-a direct aspiration first-pass technique(ADAPT)in the treatment of acute anterior circulation aorta embolic stroke.Methods The clinical data of 12 patients with acute anterior circulation arterial embolic stroke treated by modified-ADAPT in our hospital from March 2022 to February 2023 were analyzed retrospectively.The core of the modified technique is that the head of the thrombus aspiration catheter or intracranial support catheter clearly crosses the thrombus before manual continuous suction with a 20 mL syringe.After operation,all patients started standard anticoagulant therapy according to clinical symptoms and imaging manifestations,and monthly outpatient follow-up was conducted to observe whether there was recurrent stroke.Results Occlusive vessels were successfully recanalized in 12 patients,including 3 cases(25%)of mTICI 2b-2c grade and 9 cases(75%)of mTICI 3 grade.The average time from puncture to vascular recanalization was 37.7 min,and the first thrombectomy and recanalization was performed in 8 cases(66.7%).The success rate of internal carotid artery occlusion was 80%.The average NIHSSS score at discharge was(9.00±9.22).Compared with the preoperative NIHSS score,the average score decreased by 7 points.90 days after operation,the function recovered well in 9 cases(75%).Postoperative cerebral hemorrhage occurred in 3 cases(25%),including 1 case of punctate hemorrhage without obvious symptoms,1 case of good recovery of PH1 and 1 case of automatic discharge after PH2.12 patients were found to have atrial fibrillation after screening,9 patients had no recurrence after anticoagulation secondary prevention management according to clinical symptoms and imaging manifestations.Conclusions Modified-ADAPT is a safe and feasible choice for the treatment of acute arterial embolism stroke,with high recanalization efficiency,low thrombus escape probability and good clinical effect.Standardized anticoagulation management can effectively prevent the recurrence of stroke in patients with atrial fibrillation.